CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
89 hedge funds and large institutions have $116M invested in CTI BioPharma Corp. (DE) Common Stock in 2014 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 27 reducing their positions, and 24 closing their positions.
304% more call options, than puts
Call options by funds: $2.46M | Put options by funds: $608K
7% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 27
4% less funds holding
Funds holding: 93 → 89 (-4)
17% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 24
24% less capital invested
Capital invested by funds: $152M → $116M (-$36M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.08M |
| 2 |
TA
Teachers Advisors
New York
|
+$1.93M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.35M |
| 4 |
Millennium Management
New York
|
+$1.08M |
| 5 |
Jane Street
New York
|
+$974K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$4.59M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.4M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$3.37M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$2.34M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.86M |
CTIC Hedge Fund Activity: Q2 2014 in Review
89 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q2 2014, worth a combined $116M — down 24% from $152M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CTIC and 20 opened new positions — a net loss of 4 holders — while 27 trimmed existing stakes and 25 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $2.08M. The largest seller was TFS Capital, exiting entirely with an estimated $4.59M sold.
- 89 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q2 2014, down from 93 in Q1 2014.
- Funds reported $116M of CTI BioPharma Corp. (DE) Common Stock stock for Q2 2014, down 24% quarter-over-quarter.
- 20 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q2 2014 and 24 closed out, a net change of -4 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q2 2014 was Renaissance Technologies, an estimated $2.08M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q2 2014 was TFS Capital, an estimated $4.59M sold.
Based on aggregated 13F filings for Q2 2014.